JP2018536628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536628A5 JP2018536628A5 JP2018516418A JP2018516418A JP2018536628A5 JP 2018536628 A5 JP2018536628 A5 JP 2018536628A5 JP 2018516418 A JP2018516418 A JP 2018516418A JP 2018516418 A JP2018516418 A JP 2018516418A JP 2018536628 A5 JP2018536628 A5 JP 2018536628A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- antigen
- binding portion
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238680P | 2015-10-07 | 2015-10-07 | |
| US62/238,680 | 2015-10-07 | ||
| PCT/US2016/056032 WO2017062792A1 (en) | 2015-10-07 | 2016-10-07 | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536628A JP2018536628A (ja) | 2018-12-13 |
| JP2018536628A5 true JP2018536628A5 (https=) | 2019-10-17 |
Family
ID=58488607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516418A Pending JP2018536628A (ja) | 2015-10-07 | 2016-10-07 | 新規炭水化物抗体、医薬組成物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501532B2 (https=) |
| EP (1) | EP3359193A4 (https=) |
| JP (1) | JP2018536628A (https=) |
| KR (1) | KR20180077181A (https=) |
| CN (1) | CN108472362B (https=) |
| AR (1) | AR106307A1 (https=) |
| AU (1) | AU2016335842A1 (https=) |
| BR (1) | BR112018006140A2 (https=) |
| CA (1) | CA3000531A1 (https=) |
| IL (1) | IL257956A (https=) |
| TW (1) | TWI704159B (https=) |
| WO (1) | WO2017062792A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014391422A1 (en) | 2013-09-17 | 2015-12-17 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CN109379889A (zh) | 2016-04-22 | 2019-02-22 | 台湾浩鼎生技股份有限公司 | 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法 |
| KR20230117482A (ko) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| WO2018023121A1 (en) | 2016-07-29 | 2018-02-01 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| TWI822055B (zh) * | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| EP3630182A4 (en) * | 2017-05-24 | 2021-02-24 | Development Center for Biotechnology | HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT |
| IL277174B2 (en) * | 2018-03-13 | 2025-12-01 | Hoffmann La Roche | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
| WO2019232519A1 (en) * | 2018-06-01 | 2019-12-05 | Obi Pharma, Inc. | Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| CN116589572B (zh) * | 2023-06-28 | 2023-11-10 | 湖南诺合新生物科技有限公司 | 一种抗ha标签的单克隆抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| US8551920B2 (en) * | 2005-02-01 | 2013-10-08 | Morpho Sys AG | Libraries and methods for isolating antibodies |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| TWI392502B (zh) * | 2009-06-16 | 2013-04-11 | Academia Sinica | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
| CN102884085B (zh) | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
| JP6293659B2 (ja) | 2011-07-01 | 2018-03-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗プロペルジン抗体およびその使用 |
| WO2015015629A1 (ja) | 2013-08-02 | 2015-02-05 | 株式会社日立製作所 | 炭化珪素半導体装置および炭化珪素半導体装置の製造方法 |
| CN104693305A (zh) * | 2013-12-04 | 2015-06-10 | 苏州中赢医疗科技有限公司 | 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用 |
| EP3119424A4 (en) * | 2014-03-19 | 2017-09-13 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| CA2941029C (en) * | 2014-04-10 | 2021-02-16 | Obi Pharma Inc. | Antibodies, pharmaceutical compositions and uses thereof |
-
2016
- 2016-10-07 KR KR1020187012974A patent/KR20180077181A/ko not_active Withdrawn
- 2016-10-07 AU AU2016335842A patent/AU2016335842A1/en not_active Abandoned
- 2016-10-07 AR ARP160103089A patent/AR106307A1/es unknown
- 2016-10-07 WO PCT/US2016/056032 patent/WO2017062792A1/en not_active Ceased
- 2016-10-07 CN CN201680056209.7A patent/CN108472362B/zh active Active
- 2016-10-07 BR BR112018006140A patent/BR112018006140A2/pt not_active IP Right Cessation
- 2016-10-07 EP EP16854440.1A patent/EP3359193A4/en not_active Withdrawn
- 2016-10-07 TW TW105132620A patent/TWI704159B/zh active
- 2016-10-07 US US15/288,562 patent/US10501532B2/en active Active
- 2016-10-07 CA CA3000531A patent/CA3000531A1/en not_active Abandoned
- 2016-10-07 JP JP2018516418A patent/JP2018536628A/ja active Pending
-
2018
- 2018-03-07 IL IL257956A patent/IL257956A/en unknown
-
2019
- 2019-08-21 US US16/547,009 patent/US11236154B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536628A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2020536888A5 (https=) | ||
| WO2016077840A3 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| HRP20201219T1 (hr) | Anti-vla-4 antitijela | |
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2018501197A5 (https=) | ||
| EA201000785A1 (ru) | Композиции для доставки в легкие | |
| JP2016521688A5 (https=) | ||
| JP2017149720A5 (https=) | ||
| JP2015506912A5 (https=) | ||
| EA201100228A1 (ru) | Структурные варианты антител для улучшения терапевтических характеристик | |
| EA201391789A1 (ru) | TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| CY1111337T1 (el) | Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων | |
| EP2170062A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES | |
| EA201190116A1 (ru) | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 | |
| RU2017145268A (ru) | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов | |
| PH12020552235A1 (en) | Anti-cd40 antibodies for use in treating autoimmune disease | |
| JP2016094424A5 (https=) | ||
| SA523440622B1 (ar) | أجسام مضادة | |
| RU2017132827A (ru) | Антитело к notch4 человека | |
| EA202092162A1 (ru) | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака |